Recent Updates
Recently added Catalysts
AAPG Positive Sentiment Score: 80/100

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly d

Key Takeaway: Ascentage Pharma Group International successfully held its Annual General Meeting (AGM) on May 19, 2025, where all proposed resolutions were passed by shareholders. The resolutions included the adoption of the financial statements for the year ended December 31, 2024, and the re-election of several directors. The polls showed overwhelming approval for the resolutions, reflecting strong shareholder support for the company's governance and operational agenda.

Market Sentiment Analysis

POSITIVE FACTORS

  • All proposed resolutions at the AGM were unanimously passed.
  • No shareholders were required to abstain from voting, indicating full participation.
  • High percentage of shareholder approval for all major resolutions demonstrates confidence in management.

Full Press Release Details

Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,
make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising
from or in reliance upon the whole or any part of the contents of this announcement.
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Incorporated in the Cayman
Islands with limited liability)
POLL RESULTS OF THE ANNUAL
GENERAL MEETING HELD ON MAY 19, 2025
The Board is pleased to announce that all the proposed resolutions as set out in the AGM Notices dated April 16, 2025 and dated April
30, 2025 were duly passed by the Shareholders of the Company at the AGM held on May 19, 2025 by way of poll.
Reference are made to the circular
of Ascentage Pharma Group International (the "Company") dated April 16, 2025 and the supplemental circular of the Company
dated April 30, 2025 (collectively, the "AGM Circulars") and the notice of the annual general meeting (the "AGM")
of the Company dated April 16, 2025 and the supplemental notice of the AGM of the Company dated April 30, 2025 (collectively, the "AGM
Notices"). Terms used in this announcement shall have the same meanings as those defined in the AGM Circulars and the AGM Notices
unless the context requires otherwise.
POLL RESULTS OF THE AGM
As at the date of the AGM, the number
of Shares in issue was 348,448,983 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against
all the resolutions proposed at the AGM. There were no Shareholders who were entitled to attend the AGM but were required to abstain from
voting in favour of any of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required
to abstain from voting on any of the resolutions proposed at the AGM. No Shareholder was entitled to attend and vote only against any
of the resolutions proposed at the AGM. No parties had stated their intention in the AGM Circulars to vote against or to abstain from
voting on any of the resolutions at the AGM.
The Board is pleased to announce
that all the proposed resolutions as set out in the AGM Notices were duly passed by the Shareholders by way of poll at the AGM. The poll
results of all the resolutions proposed at the AGM are as follows:
Ordinary Resolutions * Number of votes cast (approximate percentage of total number of votes)
For Against
1. To consider and adopt the audited consolidated financial statements of the Company and the reports of the Directors and the auditor for the year ended December 31, 2024. 86,401,154 (100.00%) 0 (0.00%)
2(a). To re-elect Dr. Yang Dajun as an Executive Director. 86,279,038 (99.86%) 122,116 (0.14%)
2(b). To re-elect Mr. Ye Changqing as an Independent Non- executive Director. 85,249,930 (98.67%) 1,151,224 (1.33%)
2(c). To re-elect Ms. Marina S. Bozilenko as an Independent Non- executive Director. 86,399,154 (99.99%) 2,000 (0.01%)
2(d). To re-elect Dr. Debra Yu as an Independent Non-executive Director. 86,399,154 (99.99%) 2,000 (0.01%)
2(e). To re-elect Marc E. Lippman, MD as an Independent Non- executive Director. 86,399,154 (99.99%) 2,000 (0.01%)
3. To authorize the Board to fix the Directors' remuneration. 86,358,472 (99.95%) 42,682 (0.05%)
4. To re-appoint Ernst &Young as auditor of the Company, to hold office until the conclusion of the next annual general meeting of the Company, and to authorize the Board to fix their remuneration. 86,241,454 (99.82%) 159,700 (0.18%)
5. To grant a general mandate to the Directors to allot, issue and deal with new shares of the Company with an aggregate number of not exceeding 20% of the total number of shares of the Company in issue (excluding Treasury Shares, if any) as at the date of the passing of the relevant resolution at the AGM. 74,862,622 (86.65%) 11,538,532 (13.35%)
6. To grant a general mandate to the Directors to repurchase the Company's shares with a total number of not more than 10% of the total number of shares of the Company in issue (excluding Treasury Shares, if any) as at the date of the passing of the relevant resolution at the AGM. 86,401,154 (100.00%) 0 (0.00%)
Ordinary Resolutions * Number of votes cast (approximate percentage of total number of votes)
For Against
7. To extend the general mandate granted to the Directors under resolution 5 by an amount representing the aggregate number of the Company's shares repurchased by the Company under resolution 6, provided that such amount shall not exceed 10% of the total number of shares of the Company in issue (excluding Treasury Shares, if any) as at the date of the passing of the relevant resolution at the AGM. 74,909,305 (86.70%) 11,491,849 (13.30%)
8. To consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the proposed amendments to the 2021 RSU Scheme be and are hereby approved and confirmed. 75,388,120 (87.76%) 10,512,962 (12.24%)
9. To consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the proposed amendments to the 2022 RSU Scheme be and are hereby approved and confirmed. 75,388,120 (87.76%) 10,512,962 (12.24%)
10. To consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the proposed amendments to the Post- IPO Share Option Scheme be and are hereby approved and confirmed. 75,388,036 (87.76%) 10,513,046 (12.24%)
11. To consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the Scheme Mandate Limit on the total number of Shares that may be issued in respect of all options and awards to the eligible participants under all the Share Schemes of the Company be and is hereby approved and confirmed. 76,483,498 (89.04%) 9,417,584 (10.96%)
12. Conditional upon the passing of the ordinary resolution numbered 11, to consider and, if thought fit, pass (with or without amendments), the following resolution as an ordinary resolution that: the Service Provider Sublimit on the total number of Shares that may be issued in respect of all options and awards to be granted to the Service Providers under all the Share Schemes of the Company be and is hereby approved and confirmed. 76,483,498 (89.04%) 9,417,584 (10.96%)
Tricor Investor Services Limited,
the Company's Hong Kong Branch Share Registrar, acted as the scrutineer at the AGM for the purpose of vote-taking. As more than
50% of the votes were cast in favour of each of the resolutions 1 to 12, these resolutions were duly passed as ordinary resolutions at
the AGM. The following Directors attended the AGM either in person or by electronic means: Dr. Yang Dajun, Dr. Wang Shaomeng, Mr. Ye Changqing,
Mr. Ren Wei and Dr. David Sidransky.
Suzhou, People's Republic of China, May 19, 2025
the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director; Dr.
Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors; and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky, Ms. Marina
S. Bozilenko, Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.

Frequently Asked Questions

What were the AGM results for Ascentage Pharma?

All proposed resolutions were approved by shareholders at the AGM on May 19, 2025.

Who attended the AGM held on May 19, 2025?

Directors including Dr. Yang Dajun, Dr. Wang Shaomeng, and others attended.

How many shares were issued before the AGM?

There were 348,448,983 shares issued as of the AGM date.

Was there any shareholder abstaining from voting?

No shareholders were required to abstain from voting on any resolutions.

Who served as the scrutineer during the AGM?

Tricor Investor Services Limited acted as the scrutineer for the AGM.

Last updated: May 20, 2025